Plus Therapeutics (NASDAQ:PSTV) Shares Down 6.9% – Here’s What Happened

Plus Therapeutics, Inc. (NASDAQ:PSTV)’s share price fell 6.9% during mid-day trading on Wednesday . The stock traded as low as $0.34 and last traded at $0.35. 4,557,964 shares traded hands during trading, a decline of 13% from the average session volume of 5,269,079 shares. The stock had previously closed at $0.38.

Analyst Ratings Changes

Several brokerages recently issued reports on PSTV. D. Boral Capital restated a “hold” rating on shares of Plus Therapeutics in a research report on Monday, May 5th. Ascendiant Capital Markets lifted their price objective on Plus Therapeutics from $19.00 to $20.00 and gave the stock a “buy” rating in a research report on Monday, April 21st. D Boral Capital downgraded Plus Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, May 5th. Finally, HC Wainwright cut their price target on Plus Therapeutics from $8.00 to $5.50 and set a “buy” rating for the company in a report on Friday, March 28th.

Plus Therapeutics Price Performance

The firm’s 50-day moving average price is $0.62 and its 200 day moving average price is $0.97. The firm has a market cap of $6.00 million, a P/E ratio of -0.14 and a beta of 0.88.

Plus Therapeutics (NASDAQ:PSTV) last released its quarterly earnings data on Friday, May 30th. The company reported ($0.56) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.39). The company had revenue of $1.06 million for the quarter, compared to analysts’ expectations of $1.11 million. Analysts forecast that Plus Therapeutics, Inc. will post -2.3 earnings per share for the current year.

Institutional Investors Weigh In On Plus Therapeutics

An institutional investor recently bought a new position in Plus Therapeutics stock. Virtu Financial LLC purchased a new stake in Plus Therapeutics, Inc. (NASDAQ:PSTV) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 40,030 shares of the company’s stock, valued at approximately $38,000. Virtu Financial LLC owned 0.24% of Plus Therapeutics at the end of the most recent quarter. Institutional investors own 3.28% of the company’s stock.

Plus Therapeutics Company Profile

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.